ArticleBMC cardiovascular disorders2026
Association of metabolic dysfunction-associated steatotic liver disease with coronary plaque vulnerability and prognosis in patients with acute coronary syndrome.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a risk factor for cardiovascular events. However, MASLD's relationship with optical coherence tomography (OCT)-defined coronary plaque vulnerability in patients with acute coronary syndrome (ACS) remains unclear. Moreover, the mediating role of plaque vulnerability in the association between MASLD and major adverse cardiovascular and cerebrovascular events (MACCE) has rarely been investigated. Therefore, this study used OCT to examine the association between MASLD and coronary plaque vulnerability in ACS patients, to assess the impact of MASLD on MACCE, and to explore whether plaque vulnerability mediates this relationship.
methodsA total of 820 patients with ACS were enrolled in this study. All patients underwent OCT-guided percutaneous coronary intervention (PCI) and completed abdominal ultrasound (US) or non-contrast computed tomography (CT) examinations. Patients meeting the diagnostic criteria for MASLD were categorized into the MASLD group, while those who did not were assigned to the non-MASLD group.
resultsThe MASLD group had a significantly higher prevalence of multivessel disease, more complex coronary artery disease on OCT, and higher detection rates of lipid-rich plaques, cholesterol crystals, and thin-cap fibroatheroma (TCFA). Multivariate analysis confirmed that MASLD was independently associated with these vulnerable plaque features and served as an independent risk factor for major adverse cardiovascular and cerebrovascular events (MACCE) (adjusted hazard ratio [aHR] = 2.05, 95% confidence interval [CI]: 1.34-3.14, P < 0.001). Notably, plaque vulnerability, as represented by cholesterol crystals and TCFA, partially mediated the association between MASLD and MACCE, with mediation proportions of 9.90% and 23.70%, respectively.
conclusionIn patients with ACS, MASLD is associated with more complex coronary artery disease and increased plaque vulnerability assessed by OCT. Furthermore, MASLD is an independent risk factor for MACCE, and this association is partially mediated by plaque vulnerability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.